MAINSAIL TRIAL Metastatic CRPC Chemo-naïve Disease Progression
{"Image DocumentName": "MAINSAIL TRIAL Metastatic CRPC Chemo-na\u00efve Disease Progression", "Image ImageDescription": "Screening. CRPC Patients N= 1,015. Randomize 1:1. Docetaxel/Prednisone + Placebo Until Progression or Toxicity. N ~ 500. Docetaxel/Prednisone + Lenalidomide Until Progression or Toxicity. Follow-Up: For Survival. For Other Treatments. Up to five years.", "Image XResolution": "37", "Image YResolution": "37", "Image ResolutionUnit": "Pixels/Centimeter", "Image Software": "SlidePlayer", "Image YCbCrPositioning": "Centered"}